1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
657022886B4106EFD65257EA6004358BB
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/best-practices-role-of-medical-affairs-in-oncology-launch-excellence?opendocument
18
19opendocument
2018.224.32.86
21
22
23www.globalbenchmarking.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Launch Optimization

Best Practices and the Role of Medical Affairs in Oncology Launch Excellence

ID: POP-265


Features:

14 Info Graphics

12 Data Graphics

100+ Metrics

6 Narratives


Pages: 36


Published: Pre-2019


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
A rapidly changing marketplace, coupled with a restricted promotional environment have pushed the Medical Affairs (MA) function beyond its traditional support role into a more prominent oncology launch role that extends from the pre-launch phase to well beyond market entry.

From identification and engagement of key thought leaders to guidance of commercial strategies and launch resources management, the Medical Affairs function plays a vital role in a host of oncology launch activities.

Best Practices, LLC undertook this study to help companies focused on oncology therapies find better ways to develop successful launch strategies. This research delivers current data, insights and best practices in oncology launch excellence from Medical Affairs leaders at top biopharmaceutical companies.


Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Biopharmaceutical; Consulting; Health Care; Clinical Research; Laboratories


Companies Profiled:
Astellas; Bayer; Incyte; Insyght; Insys Therapeutics; Merck; Onyx Pharmaceuticals; ProStrakan; Roche; Sanofi; Jazz Pharmaceuticals

Study Snapshot

This study engaged 11 executives from leading life sciences companies. The study analyzes companies that focus on oncology therapies.

Key Findings

§ Medical Affairs’ Role in Launch Activities: Medical Affairs is heavily involved in four launch activities within participating organizations: Scientific Publications, Continuing Medical Education, Real World Data Generation & Analysis, MSL activities.

    § Medical Affairs leads TL Activities and plays a key role between companies and decision makers during launch process. This requires companies to create strong MSL teams, acquire the right talent and provide effective training.

    § Medical Affairs also plays a critical role in internal education and guiding commercial strategies regarding products. This provides Medical Affairs leaders with the opportunity to convey the needs of key decision makers, thus companies to improve their products.
Table of Contents

§ Executive Summary pp. 3-8
      ü Research Overview pp. 3
      ü Participating Companies pp. 4
      ü Key Recommendations pp. 5
      ü Abbreviations pp. 6
      ü Key Findings & Insights pp. 7-8
§ Medical Affairs' Role in Launch Activities pp. 9-12
§ Thought Leader Tiering pp. 13-16
§ Thought Leader Targeting and MSL Coverage pp. 17-22
§ Launch Investment pp. 23-27
§ Medical Affairs Investment Allocation pp. 28-30
§ Participant Overview pp. 31-34

List of Charts & Exhibits

§ Medical Affairs' Role in Launch Activities
§ Role of Medical Affairs in Internal Product Launch Communication
§ Thought Leader Tiering Criteria
§ Timing of Strategies Used for Thought-Leader (TL) Tiering
§ Case Example: Thought Leader Segmentation Process
§ Number of Thought Leaders Targeted During Pre-Launch and Post-Launch
§ Number of MSLs Employed During Pre-Launch and Post-Launch
§ Number of TLs Targeted Per MSLs Employed During Pre-Launch and Post-Launch
§ Core Responsibilities
§ Total Launch Investment - Pre-Launch and Post-Launch
§ Total Medical Affairs Launch Investment - Pre-Launch and Post-Launch
§ Number of Medical Affairs Launch FTEs per Product - Pre-Launch and Post-Launch
§ Percentage of Total Medical Affairs Launch Investment Allocated to Listed Medical Affairs Activities
§ Launch Success Factors